Job Cuts As Nordic Nanovector Extends Cash Runway
Biotech’s Priority Is Pivotal Betalutin Study But COVID-19 Uncertainty Remains
Executive Summary
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
You may also be interested in...
Nordic Nanovector To Restructure After Discontinuing Lymphoma Trial
The company still sees a potential future for Betalutin and hopes to partner the asset as it looks to focus on the rest of its pipeline.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.